Search

Displaying results 2351 - 2360 of 10000 in total
  1. Drug

    Elafibranor

    go.drugbank.com/drugs/DB05187
    ApprovedInvestigational

    Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersSynonyms: PROPANOIC ACID, 2-(2,6-DIMETHYL-4-((1E)-3-(4-(METHYLTHIO)PHENYL)-3-OXO-1-PROPEN-1-YL)PHENOXY)-, PROPANOIC ACID, 2-(2,6-DIMETHYL-4-(3-(4-(METHYLTHIO)PHENYL)-3-OXO-1-PROPEN-1-YL)PHENOXY)-2-METHYL-
  2. Drug

    KD3010

    go.drugbank.com/drugs/DB05188
    Experimental

    KD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity.

    Categories: Heterocyclic Compounds, 1-Ring
  3. Drug

    EPC2407

    go.drugbank.com/drugs/DB05189
    Investigational

    EPC2407 is a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas. … It is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized.

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  4. Drug

    Sofalcone

    go.drugbank.com/drugs/DB05197
    Experimental

    by H. pylori. … Sofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. on adherence, production of vacuolating toxin (VT), and induction of interleukin-8 (IL-8) secretion

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  5. Drug

    V24343

    go.drugbank.com/drugs/DB05201
    Investigational

    The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.

  6. Drug

    Egaptivon pegol

    go.drugbank.com/drugs/DB05202
    Investigational

    Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. … [A3290, A259053] Egaptivon pegol is a therapeutic oligonucleotide ("aptamer") which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, thereby modulating platelet adhesion, activation

  7. Drug

    SPP1148

    go.drugbank.com/drugs/DB05203
    Experimental

    SPP1148, the most promising compound from a new series of renin inhibitors for the treatment of hypertension and related end-organ disease.

  8. Drug

    CX157

    go.drugbank.com/drugs/DB05205
    Investigational

    CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous … MAO-A inhibitors of this class.

  9. Drug

    SD118

    go.drugbank.com/drugs/DB05207
    Experimental

    SD118 was previously under investigation in Japan for a different indication and now, following re-profiling and evaluation in experimental animal models, has demonstrated its potential as a new oral therapy

  10. Drug

    KB001

    go.drugbank.com/drugs/DB05222
    Investigational

    KB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated